Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous (in the belly area) formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 16-24 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 3 years and followed actively for 52 weeks. There are a number of secondary objectives that will be studied as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis B (HBV) and C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of depression and posttraumatic stress disorder, housing status, dental health and utilization, and cost-effectiveness.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Sublingual buprenorphine with naloxone
- drug: Injectable subcutaneous buprenorphine
Eligibility
Inclusion Criteria:
- Has used opioids within 30 days prior to consent or within 30 days prior to entry into
a supervised setting -- e.g., opioid use within the 30 days prior to recent (<30 days)
incarceration, entry into a detoxification facility, or entry into an inpatient
hospital setting
- Have started on MOUD via clinical induction on SL-BUP/NLX
- Meets DSM-5 criteria for moderate to severe OUD based on the Mini-International
Neuropsychiatric Interview
- Referred to/seeking treatment for OUD and willing to accept "partial-agonist-based"
therapy
Exclusion Criteria:
- Is a Veteran less than 18 years of age
- For Veterans of childbearing potential (a premenopausal person capable of becoming
pregnant), pregnancy, breastfeeding, and/or failure to practice an effective method of
birth control
- Taking a form of prescribed maintenance MOUD (e.g., methadone, buprenorphine or
XR-NTX) continuously >30 days prior to consent.
- Taking a form of prescribed maintenance MOUD (e.g., methadone, buprenorphine or
XR-NTX) continuously >45 days prior to randomization
- Has a history of significant adverse effects from buprenorphine and/or naloxone
- Has experienced (within the past 2 weeks) recent suicidal or homicidal ideation that
requires acute treatment or hospitalization.
- Is unwilling or unable to provide consent
- Meets criteria for current (past month) DSM-5 severe sedative hypnotic use disorder
based on the MINI SHUD module
- Is determined unsuitable for study participation based on the clinical judgement of
the LSI or Co-I given results of a CIWA-Ar, physical exam, and/or liver or kidney
function tests and/or blood tests
- Has any other medical, psychiatric, behavioral, or logistical condition which, in the
judgement of the LSI or Co-I, makes it unlikely the participant can participate in or
complete the 52-week active phase of the study
- Is actively participating in an interventional clinical trial for which a waiver of
dual-enrollment with CSP#2014 has not been obtained
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michael Ostacher, MD
650-849-0494
I'm interested
Psoriasis Clinical Trials
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous (in the belly area) formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 16-24 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 3 years and followed actively for 52 weeks. There are a number of secondary objectives that will be studied as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis B (HBV) and C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of depression and posttraumatic stress disorder, housing status, dental health and utilization, and cost-effectiveness.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Sublingual buprenorphine with naloxone
- drug: Injectable subcutaneous buprenorphine
Eligibility
Inclusion Criteria:
- Has used opioids within 30 days prior to consent or within 30 days prior to entry into
a supervised setting -- e.g., opioid use within the 30 days prior to recent (<30 days)
incarceration, entry into a detoxification facility, or entry into an inpatient
hospital setting
- Have started on MOUD via clinical induction on SL-BUP/NLX
- Meets DSM-5 criteria for moderate to severe OUD based on the Mini-International
Neuropsychiatric Interview
- Referred to/seeking treatment for OUD and willing to accept "partial-agonist-based"
therapy
Exclusion Criteria:
- Is a Veteran less than 18 years of age
- For Veterans of childbearing potential (a premenopausal person capable of becoming
pregnant), pregnancy, breastfeeding, and/or failure to practice an effective method of
birth control
- Taking a form of prescribed maintenance MOUD (e.g., methadone, buprenorphine or
XR-NTX) continuously >30 days prior to consent.
- Taking a form of prescribed maintenance MOUD (e.g., methadone, buprenorphine or
XR-NTX) continuously >45 days prior to randomization
- Has a history of significant adverse effects from buprenorphine and/or naloxone
- Has experienced (within the past 2 weeks) recent suicidal or homicidal ideation that
requires acute treatment or hospitalization.
- Is unwilling or unable to provide consent
- Meets criteria for current (past month) DSM-5 severe sedative hypnotic use disorder
based on the MINI SHUD module
- Is determined unsuitable for study participation based on the clinical judgement of
the LSI or Co-I given results of a CIWA-Ar, physical exam, and/or liver or kidney
function tests and/or blood tests
- Has any other medical, psychiatric, behavioral, or logistical condition which, in the
judgement of the LSI or Co-I, makes it unlikely the participant can participate in or
complete the 52-week active phase of the study
- Is actively participating in an interventional clinical trial for which a waiver of
dual-enrollment with CSP#2014 has not been obtained
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michael Ostacher, MD
650-849-0494
I'm interested
Dermatology Clinical Trials
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous (in the belly area) formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 16-24 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 3 years and followed actively for 52 weeks. There are a number of secondary objectives that will be studied as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis B (HBV) and C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of depression and posttraumatic stress disorder, housing status, dental health and utilization, and cost-effectiveness.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Sublingual buprenorphine with naloxone
- drug: Injectable subcutaneous buprenorphine
Eligibility
Inclusion Criteria:
- Has used opioids within 30 days prior to consent or within 30 days prior to entry into
a supervised setting -- e.g., opioid use within the 30 days prior to recent (<30 days)
incarceration, entry into a detoxification facility, or entry into an inpatient
hospital setting
- Have started on MOUD via clinical induction on SL-BUP/NLX
- Meets DSM-5 criteria for moderate to severe OUD based on the Mini-International
Neuropsychiatric Interview
- Referred to/seeking treatment for OUD and willing to accept "partial-agonist-based"
therapy
Exclusion Criteria:
- Is a Veteran less than 18 years of age
- For Veterans of childbearing potential (a premenopausal person capable of becoming
pregnant), pregnancy, breastfeeding, and/or failure to practice an effective method of
birth control
- Taking a form of prescribed maintenance MOUD (e.g., methadone, buprenorphine or
XR-NTX) continuously >30 days prior to consent.
- Taking a form of prescribed maintenance MOUD (e.g., methadone, buprenorphine or
XR-NTX) continuously >45 days prior to randomization
- Has a history of significant adverse effects from buprenorphine and/or naloxone
- Has experienced (within the past 2 weeks) recent suicidal or homicidal ideation that
requires acute treatment or hospitalization.
- Is unwilling or unable to provide consent
- Meets criteria for current (past month) DSM-5 severe sedative hypnotic use disorder
based on the MINI SHUD module
- Is determined unsuitable for study participation based on the clinical judgement of
the LSI or Co-I given results of a CIWA-Ar, physical exam, and/or liver or kidney
function tests and/or blood tests
- Has any other medical, psychiatric, behavioral, or logistical condition which, in the
judgement of the LSI or Co-I, makes it unlikely the participant can participate in or
complete the 52-week active phase of the study
- Is actively participating in an interventional clinical trial for which a waiver of
dual-enrollment with CSP#2014 has not been obtained
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michael Ostacher, MD
650-849-0494
I'm interested
Pediatric Dermatology Clinical Trials
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous (in the belly area) formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 16-24 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 3 years and followed actively for 52 weeks. There are a number of secondary objectives that will be studied as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis B (HBV) and C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of depression and posttraumatic stress disorder, housing status, dental health and utilization, and cost-effectiveness.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Sublingual buprenorphine with naloxone
- drug: Injectable subcutaneous buprenorphine
Eligibility
Inclusion Criteria:
- Has used opioids within 30 days prior to consent or within 30 days prior to entry into
a supervised setting -- e.g., opioid use within the 30 days prior to recent (<30 days)
incarceration, entry into a detoxification facility, or entry into an inpatient
hospital setting
- Have started on MOUD via clinical induction on SL-BUP/NLX
- Meets DSM-5 criteria for moderate to severe OUD based on the Mini-International
Neuropsychiatric Interview
- Referred to/seeking treatment for OUD and willing to accept "partial-agonist-based"
therapy
Exclusion Criteria:
- Is a Veteran less than 18 years of age
- For Veterans of childbearing potential (a premenopausal person capable of becoming
pregnant), pregnancy, breastfeeding, and/or failure to practice an effective method of
birth control
- Taking a form of prescribed maintenance MOUD (e.g., methadone, buprenorphine or
XR-NTX) continuously >30 days prior to consent.
- Taking a form of prescribed maintenance MOUD (e.g., methadone, buprenorphine or
XR-NTX) continuously >45 days prior to randomization
- Has a history of significant adverse effects from buprenorphine and/or naloxone
- Has experienced (within the past 2 weeks) recent suicidal or homicidal ideation that
requires acute treatment or hospitalization.
- Is unwilling or unable to provide consent
- Meets criteria for current (past month) DSM-5 severe sedative hypnotic use disorder
based on the MINI SHUD module
- Is determined unsuitable for study participation based on the clinical judgement of
the LSI or Co-I given results of a CIWA-Ar, physical exam, and/or liver or kidney
function tests and/or blood tests
- Has any other medical, psychiatric, behavioral, or logistical condition which, in the
judgement of the LSI or Co-I, makes it unlikely the participant can participate in or
complete the 52-week active phase of the study
- Is actively participating in an interventional clinical trial for which a waiver of
dual-enrollment with CSP#2014 has not been obtained
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michael Ostacher, MD
650-849-0494
I'm interested
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous (in the belly area) formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 16-24 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 3 years and followed actively for 52 weeks. There are a number of secondary objectives that will be studied as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis B (HBV) and C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of depression and posttraumatic stress disorder, housing status, dental health and utilization, and cost-effectiveness.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Sublingual buprenorphine with naloxone
- drug: Injectable subcutaneous buprenorphine
Eligibility
Inclusion Criteria:
- Has used opioids within 30 days prior to consent or within 30 days prior to entry into
a supervised setting -- e.g., opioid use within the 30 days prior to recent (<30 days)
incarceration, entry into a detoxification facility, or entry into an inpatient
hospital setting
- Have started on MOUD via clinical induction on SL-BUP/NLX
- Meets DSM-5 criteria for moderate to severe OUD based on the Mini-International
Neuropsychiatric Interview
- Referred to/seeking treatment for OUD and willing to accept "partial-agonist-based"
therapy
Exclusion Criteria:
- Is a Veteran less than 18 years of age
- For Veterans of childbearing potential (a premenopausal person capable of becoming
pregnant), pregnancy, breastfeeding, and/or failure to practice an effective method of
birth control
- Taking a form of prescribed maintenance MOUD (e.g., methadone, buprenorphine or
XR-NTX) continuously >30 days prior to consent.
- Taking a form of prescribed maintenance MOUD (e.g., methadone, buprenorphine or
XR-NTX) continuously >45 days prior to randomization
- Has a history of significant adverse effects from buprenorphine and/or naloxone
- Has experienced (within the past 2 weeks) recent suicidal or homicidal ideation that
requires acute treatment or hospitalization.
- Is unwilling or unable to provide consent
- Meets criteria for current (past month) DSM-5 severe sedative hypnotic use disorder
based on the MINI SHUD module
- Is determined unsuitable for study participation based on the clinical judgement of
the LSI or Co-I given results of a CIWA-Ar, physical exam, and/or liver or kidney
function tests and/or blood tests
- Has any other medical, psychiatric, behavioral, or logistical condition which, in the
judgement of the LSI or Co-I, makes it unlikely the participant can participate in or
complete the 52-week active phase of the study
- Is actively participating in an interventional clinical trial for which a waiver of
dual-enrollment with CSP#2014 has not been obtained
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michael Ostacher, MD
650-849-0494
I'm interested
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous (in the belly area) formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 16-24 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 3 years and followed actively for 52 weeks. There are a number of secondary objectives that will be studied as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis B (HBV) and C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of depression and posttraumatic stress disorder, housing status, dental health and utilization, and cost-effectiveness.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Sublingual buprenorphine with naloxone
- drug: Injectable subcutaneous buprenorphine
Eligibility
Inclusion Criteria:
- Has used opioids within 30 days prior to consent or within 30 days prior to entry into
a supervised setting -- e.g., opioid use within the 30 days prior to recent (<30 days)
incarceration, entry into a detoxification facility, or entry into an inpatient
hospital setting
- Have started on MOUD via clinical induction on SL-BUP/NLX
- Meets DSM-5 criteria for moderate to severe OUD based on the Mini-International
Neuropsychiatric Interview
- Referred to/seeking treatment for OUD and willing to accept "partial-agonist-based"
therapy
Exclusion Criteria:
- Is a Veteran less than 18 years of age
- For Veterans of childbearing potential (a premenopausal person capable of becoming
pregnant), pregnancy, breastfeeding, and/or failure to practice an effective method of
birth control
- Taking a form of prescribed maintenance MOUD (e.g., methadone, buprenorphine or
XR-NTX) continuously >30 days prior to consent.
- Taking a form of prescribed maintenance MOUD (e.g., methadone, buprenorphine or
XR-NTX) continuously >45 days prior to randomization
- Has a history of significant adverse effects from buprenorphine and/or naloxone
- Has experienced (within the past 2 weeks) recent suicidal or homicidal ideation that
requires acute treatment or hospitalization.
- Is unwilling or unable to provide consent
- Meets criteria for current (past month) DSM-5 severe sedative hypnotic use disorder
based on the MINI SHUD module
- Is determined unsuitable for study participation based on the clinical judgement of
the LSI or Co-I given results of a CIWA-Ar, physical exam, and/or liver or kidney
function tests and/or blood tests
- Has any other medical, psychiatric, behavioral, or logistical condition which, in the
judgement of the LSI or Co-I, makes it unlikely the participant can participate in or
complete the 52-week active phase of the study
- Is actively participating in an interventional clinical trial for which a waiver of
dual-enrollment with CSP#2014 has not been obtained
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michael Ostacher, MD
650-849-0494
I'm interested